Orexo (ORXOF) 16.3000 $ORXOF
Orexo AB announces conversion of convertible bonds into shares
M2 - Mon Aug 26, 6:17AM CDT
Speciality pharmaceutical company Orexo AB (STO:ORX.ST) announced today the conversion of a convertible bond issue, subscribed by Novo A/S, into shares on 23 August 2013.
U.S. FDA Approves Zubsolv® for the Maintenance Treatment of Opioid Dependence
PR Newswire - Fri Jul 05, 7:00AM CDT
Orexo U.S., Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII). Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with higher bioavailability, a fast dissolve time, smaller tablet size and a new menthol flavor.
Orexo's Zubsolv receives US FDA approval
M2 - Thu Jul 04, 10:55AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the receipt of approval from the US Food and Drug Administration (FDA) for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII.
Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi
2 Bio Stock Reports: (NASDAQ: GALE), (NASDAQ: ARRY)
ACCESSWIRE-TNW - Tue Mar 26, 2:20AM CDT
New York (March 26th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced last week that it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.
2 BIO Stocks in the News: (NASDAQ: GALE), (NYSE: NAVB)
ACCESSWIRE-TNW - Tue Mar 19, 12:22AM CDT
New York (March 19th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.
Orexo sells Abstral in the US to Galena Biopharma for USD10m upfront
M2 - Mon Mar 18, 1:40PM CDT
Speciality pharma company Orexo AB (STO:ORX.ST) announced today the sale of Abstral (fentanyl) sublingual tablets in the US to Galena Biopharma Inc (Nasdaq:GALE), a biopharmaceutical company.
Orexo AB announces divestiture of Abstral in the US for USD10m upfront
M2 - Mon Mar 18, 6:50AM CDT
Specialist pharma company Orexo AB (Stockholm:ORX.ST) revealed on Monday the sale of its FDA approved Abstral (fentanyl) Sublingual Tablets in the US to Galena Biopharma, Inc (NasdaqCM:GALE) for USD10m upfront .
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Orexo names Nikolaj Sorensen as new CEO and Martin Nicklasson as Executive Chairman
M2 - Tue Feb 05, 5:08AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) today announced that Nikolaj Sorensen, currently chief commercial officer of Orexo, will be promoted as CEO of the company.
Orexo AB announces conversion of convertible bonds into shares
M2 - Mon Aug 26, 6:17AM CDT
Speciality pharmaceutical company Orexo AB (STO:ORX.ST) announced today the conversion of a convertible bond issue, subscribed by Novo A/S, into shares on 23 August 2013.
U.S. FDA Approves Zubsolv® for the Maintenance Treatment of Opioid Dependence
PR Newswire - Fri Jul 05, 7:00AM CDT
Orexo U.S., Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII). Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with higher bioavailability, a fast dissolve time, smaller tablet size and a new menthol flavor.
Orexo's Zubsolv receives US FDA approval
M2 - Thu Jul 04, 10:55AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the receipt of approval from the US Food and Drug Administration (FDA) for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII.
Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi
2 Bio Stock Reports: (NASDAQ: GALE), (NASDAQ: ARRY)
ACCESSWIRE-TNW - Tue Mar 26, 2:20AM CDT
New York (March 26th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced last week that it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.
2 BIO Stocks in the News: (NASDAQ: GALE), (NYSE: NAVB)
ACCESSWIRE-TNW - Tue Mar 19, 12:22AM CDT
New York (March 19th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.
Orexo sells Abstral in the US to Galena Biopharma for USD10m upfront
M2 - Mon Mar 18, 1:40PM CDT
Speciality pharma company Orexo AB (STO:ORX.ST) announced today the sale of Abstral (fentanyl) sublingual tablets in the US to Galena Biopharma Inc (Nasdaq:GALE), a biopharmaceutical company.
Orexo AB announces divestiture of Abstral in the US for USD10m upfront
M2 - Mon Mar 18, 6:50AM CDT
Specialist pharma company Orexo AB (Stockholm:ORX.ST) revealed on Monday the sale of its FDA approved Abstral (fentanyl) Sublingual Tablets in the US to Galena Biopharma, Inc (NasdaqCM:GALE) for USD10m upfront .
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Orexo names Nikolaj Sorensen as new CEO and Martin Nicklasson as Executive Chairman
M2 - Tue Feb 05, 5:08AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) today announced that Nikolaj Sorensen, currently chief commercial officer of Orexo, will be promoted as CEO of the company.
